百濟神州(06160.HK)廣州基地生產「百澤安」首次向澳門商業化供貨
百濟神州(06160.HK)(BGNE.US)公布,自主研發的PD-1抑製劑「百澤安」(替雷利珠單抗),已於今日(21日)從廣州生物藥生產基地發送,並運抵澳門分銷商倉庫,為首批從該基地出口至澳門的商業化供貨。至此,百濟神州中國廣州基地和蘇州創新藥物產業化基地(蘇州基地)雙雙開啟「出口」新篇章。
公司總裁兼首席運營官吳曉濱表示,欣喜看到公司兩大生產基地所生產的產品均已出口,期望為全球越來越多地區和市場的患者提供更多治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.